Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma.

Martinez-Usatorre A, Sempere LF, Carmona SJ, Carretero-Iglesia L, Monnot G, Speiser DE, Rufer N, Donda A, Zehn D, Jandus C, Romero P.

Cancer Immunol Res. 2019 Jun;7(6):1013-1024. doi: 10.1158/2326-6066.CIR-18-0504. Epub 2019 May 1.

PMID:
31043416
2.

Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms.

Presotto D, Erdes E, Duong MN, Allard M, Regamey PO, Quadroni M, Doucey MA, Rufer N, Hebeisen M.

Front Immunol. 2017 Nov 15;8:1564. doi: 10.3389/fimmu.2017.01564. eCollection 2017.

3.

TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency.

Allard M, Couturaud B, Carretero-Iglesia L, Duong MN, Schmidt J, Monnot GC, Romero P, Speiser DE, Hebeisen M, Rufer N.

JCI Insight. 2017 Jul 20;2(14). pii: 92570. doi: 10.1172/jci.insight.92570. eCollection 2017 Jul 20.

4.

Heterogeneity assessment of functional T cell avidity.

Ioannidou K, Baumgaertner P, Gannon PO, Speiser MF, Allard M, Hebeisen M, Rufer N, Speiser DE.

Sci Rep. 2017 Mar 13;7:44320. doi: 10.1038/srep44320.

5.

Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients.

Gannon PO, Baumgaertner P, Huber A, Iancu EM, Cagnon L, Abed Maillard S, Maby-El Hajjami H, Speiser DE, Rufer N.

Clin Cancer Res. 2017 Jul 1;23(13):3285-3296. doi: 10.1158/1078-0432.CCR-16-1708. Epub 2016 Nov 21.

6.

TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer.

Bron S, Henry L, Faes-Van't Hull E, Turrini R, Vanhecke D, Guex N, Ifticene-Treboux A, Marina Iancu E, Semilietof A, Rufer N, Lehr HA, Xenarios I, Coukos G, Delaloye JF, Doucey MA.

Oncoimmunology. 2015 Aug 20;5(2):e1073882. eCollection 2016 Feb.

7.

Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens.

Hebeisen M, Allard M, Gannon PO, Schmidt J, Speiser DE, Rufer N.

Front Immunol. 2015 Nov 18;6:582. doi: 10.3389/fimmu.2015.00582. eCollection 2015. Review.

8.

Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.

Legat A, Maby-El Hajjami H, Baumgaertner P, Cagnon L, Abed Maillard S, Geldhof C, Iancu EM, Lebon L, Guillaume P, Dojcinovic D, Michielin O, Romano E, Berthod G, Rimoldi D, Triebel F, Luescher I, Rufer N, Speiser DE.

Clin Cancer Res. 2016 Mar 15;22(6):1330-40. doi: 10.1158/1078-0432.CCR-15-1212. Epub 2015 Oct 23.

9.

Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence.

Gannon PO, Wieckowski S, Baumgaertner P, Hebeisen M, Allard M, Speiser DE, Rufer N.

J Immunol. 2015 Jul 1;195(1):356-66. doi: 10.4049/jimmunol.1403145. Epub 2015 May 22.

10.

Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination.

Fuertes Marraco SA, Soneson C, Cagnon L, Gannon PO, Allard M, Abed Maillard S, Montandon N, Rufer N, Waldvogel S, Delorenzi M, Speiser DE.

Sci Transl Med. 2015 Apr 8;7(282):282ra48. doi: 10.1126/scitranslmed.aaa3700.

11.

Identification of Rare High-Avidity, Tumor-Reactive CD8+ T Cells by Monomeric TCR-Ligand Off-Rates Measurements on Living Cells.

Hebeisen M, Schmidt J, Guillaume P, Baumgaertner P, Speiser DE, Luescher I, Rufer N.

Cancer Res. 2015 May 15;75(10):1983-91. doi: 10.1158/0008-5472.CAN-14-3516. Epub 2015 Mar 25.

12.

Pulmonary sarcoid-like granulomatosis after multiple vaccinations of a long-term surviving patient with metastatic melanoma.

Bordry N, Costa-Nunes CM, Cagnon L, Gannon PO, Abed-Maillard S, Baumgaertner P, Murray T, Letovanec I, Lazor R, Bouchaab H, Rufer N, Romano E, Michielin O, Speiser DE.

Cancer Immunol Res. 2014 Dec;2(12):1148-53. doi: 10.1158/2326-6066.CIR-14-0143. Epub 2014 Oct 2.

13.

Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans.

Romero P, Speiser DE, Rufer N.

Eur J Immunol. 2014 Sep;44(9):2567-70. doi: 10.1002/eji.201445004.

14.

Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients.

Iancu EM, Gannon PO, Laurent J, Gupta B, Romero P, Michielin O, Romano E, Speiser DE, Rufer N.

PLoS One. 2013 Oct 25;8(10):e78686. doi: 10.1371/journal.pone.0078686. eCollection 2013.

15.

Molecular insights for optimizing T cell receptor specificity against cancer.

Hebeisen M, Oberle SG, Presotto D, Speiser DE, Zehn D, Rufer N.

Front Immunol. 2013 Jun 19;4:154. doi: 10.3389/fimmu.2013.00154. eCollection 2013.

16.

MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer.

Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, Utzschneider DT, Escobar TM, Perret R, Muljo SA, Hebeisen M, Rufer N, Zehn D, Donda A, Restifo NP, Held W, Gattinoni L, Romero P.

Immunity. 2013 Apr 18;38(4):742-53. doi: 10.1016/j.immuni.2012.12.006.

17.

Two specific populations of GABAergic neurons originating from the medial and the caudal ganglionic eminences aid in proper navigation of callosal axons.

Niquille M, Minocha S, Hornung JP, Rufer N, Valloton D, Kessaris N, Alfonsi F, Vitalis T, Yanagawa Y, Devenoges C, Dayer A, Lebrand C.

Dev Neurobiol. 2013 Sep;73(9):647-72. doi: 10.1002/dneu.22075. Epub 2013 Aug 2.

18.

SHP-1 phosphatase activity counteracts increased T cell receptor affinity.

Hebeisen M, Baitsch L, Presotto D, Baumgaertner P, Romero P, Michielin O, Speiser DE, Rufer N.

J Clin Invest. 2013 Mar;123(3):1044-56. doi: 10.1172/JCI65325. Epub 2013 Feb 8.

19.

A stepwise protocol to coat aAPC beads prevents out-competition of anti-CD3 mAb and consequent experimental artefacts.

Fuertes Marraco SA, Baumgaertner P, Legat A, Rufer N, Speiser DE.

J Immunol Methods. 2012 Nov 30;385(1-2):90-5. doi: 10.1016/j.jim.2012.07.017. Epub 2012 Jul 31.

PMID:
22867742
20.

Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo.

Mahnke YD, Devevre E, Baumgaertner P, Matter M, Rufer N, Romero P, Speiser DE.

Oncoimmunology. 2012 Jul 1;1(4):467-530.

21.

Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation.

Gupta B, Iancu EM, Gannon PO, Wieckowski S, Baitsch L, Speiser DE, Rufer N.

J Immunother. 2012 Jul;35(6):488-501. doi: 10.1097/CJI.0b013e31826183a7.

22.

Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.

Irving M, Zoete V, Hebeisen M, Schmid D, Baumgartner P, Guillaume P, Romero P, Speiser D, Luescher I, Rufer N, Michielin O.

J Biol Chem. 2012 Jun 29;287(27):23068-78. doi: 10.1074/jbc.M112.357673. Epub 2012 May 1.

23.

Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.

Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals JP, Baumgaertner P, Christiansen-Jucht C, Bouzourene H, Rimoldi D, Pircher H, Rufer N, Matter M, Michielin O, Speiser DE.

PLoS One. 2012;7(2):e30852. doi: 10.1371/journal.pone.0030852. Epub 2012 Feb 8.

24.

Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose.

Lövgren T, Baumgaertner P, Wieckowski S, Devêvre E, Guillaume P, Luescher I, Rufer N, Speiser DE.

Cancer Immunol Immunother. 2012 Jun;61(6):817-26. doi: 10.1007/s00262-011-1140-1. Epub 2011 Nov 12.

PMID:
22080404
25.

TCRep 3D: an automated in silico approach to study the structural properties of TCR repertoires.

Leimgruber A, Ferber M, Irving M, Hussain-Kahn H, Wieckowski S, Derré L, Rufer N, Zoete V, Michielin O.

PLoS One. 2011;6(10):e26301. doi: 10.1371/journal.pone.0026301. Epub 2011 Oct 28.

26.

Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes.

Speiser DE, Wieckowski S, Gupta B, Iancu EM, Baumgaertner P, Baitsch L, Michielin O, Romero P, Rufer N.

Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15318-23. doi: 10.1073/pnas.1105419108. Epub 2011 Aug 29.

27.

Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells.

Baumgaertner P, Jandus C, Rivals JP, Derré L, Lövgren T, Baitsch L, Guillaume P, Luescher IF, Berthod G, Matter M, Rufer N, Michielin O, Speiser DE.

Int J Cancer. 2012 Jun 1;130(11):2607-17. doi: 10.1002/ijc.26297. Epub 2011 Aug 24.

28.

Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.

Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke B, Romero P, Rufer N, Speiser DE.

J Clin Invest. 2011 Jun;121(6):2350-60. doi: 10.1172/JCI46102. Epub 2011 May 9.

29.

Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination.

Iancu EM, Baumgaertner P, Wieckowski S, Speiser DE, Rufer N.

J Biomed Biotechnol. 2011;2011:452606. doi: 10.1155/2011/452606. Epub 2010 Nov 14. Review.

30.

Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.

Laurent J, Speiser DE, Appay V, Touvrey C, Vicari M, Papaioannou A, Canellini G, Rimoldi D, Rufer N, Romero P, Leyvraz S, Voelter V.

J Immunother. 2010 Sep;33(7):723-34. doi: 10.1097/CJI.0b013e3181ea7e6e.

PMID:
20664354
31.

Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function.

Schmid DA, Irving MB, Posevitz V, Hebeisen M, Posevitz-Fejfar A, Sarria JC, Gomez-Eerland R, Thome M, Schumacher TN, Romero P, Speiser DE, Zoete V, Michielin O, Rufer N.

J Immunol. 2010 May 1;184(9):4936-46. doi: 10.4049/jimmunol.1000173. Epub 2010 Mar 29.

32.

[Publications of third year medical students after their community-based internships].

Pécoud A, Daeppen JB, Hofner MC, Diserens C, Jotterand M, de Sépibus R, von Siebenthal MI, Udin I, de Allegri N, Manasseh N, Tenot C, Thorens A, Thorens O, Leuenberger A, Moser A, Perrodin S, Andrey A, Koehli L, Ribeiro S, Rufer N.

Rev Med Suisse. 2010 Feb 3;6(234):256-60. French. No abstract available.

PMID:
20334085
33.

Novel soluble HLA-A2/MELAN-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in patients with melanoma.

Guillaume P, Baumgaertner P, Neff L, Rufer N, Wettstein P, Speiser DE, Luescher IF.

Int J Cancer. 2010 Aug 15;127(4):910-23. doi: 10.1002/ijc.25099.

34.

Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.

Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, Wieckowski S, Rufer N, Kwok WW, Tiercy JM, Luescher IF, Speiser DE, Romero P.

Cancer Res. 2009 Oct 15;69(20):8085-93. doi: 10.1158/0008-5472.CAN-09-2226. Epub 2009 Oct 6.

35.

Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.

Wieckowski S, Baumgaertner P, Corthesy P, Voelter V, Romero P, Speiser DE, Rufer N.

J Immunol. 2009 Oct 15;183(8):5397-406. doi: 10.4049/jimmunol.0901460. Epub 2009 Sep 28.

36.

Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time.

Iancu EM, Corthesy P, Baumgaertner P, Devevre E, Voelter V, Romero P, Speiser DE, Rufer N.

J Immunol. 2009 Jul 1;183(1):319-31. doi: 10.4049/jimmunol.0803647.

37.

Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase.

Touvrey C, Derré L, Devevre E, Corthesy P, Romero P, Rufer N, Speiser DE.

J Immunol. 2009 Jun 1;182(11):6718-26. doi: 10.4049/jimmunol.0803095.

38.

Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors.

Bricard G, Cesson V, Devevre E, Bouzourene H, Barbey C, Rufer N, Im JS, Alves PM, Martinet O, Halkic N, Cerottini JC, Romero P, Porcelli SA, Macdonald HR, Speiser DE.

J Immunol. 2009 Apr 15;182(8):5140-51. doi: 10.4049/jimmunol.0711086.

39.

Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues.

Derré L, Bruyninx M, Baumgaertner P, Ferber M, Schmid D, Leimgruber A, Zoete V, Romero P, Michielin O, Speiser DE, Rufer N.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15010-5. doi: 10.1073/pnas.0807954105. Epub 2008 Sep 22.

40.

[New developments in cancer immunotherapy].

Michielin O, Rufer N, Romero P, Laurent J, Cerottini JP, Gugisberg D, Leyvraz S, Speiser D.

Rev Med Suisse. 2008 May 21;4(158):1248-51. Review. French.

PMID:
18616206
41.

Methods for human CD8(+) T lymphocyte proteome analysis.

Thadikkaran L, Rufer N, Benay C, Crettaz D, Tissot JD.

Methods Mol Biol. 2008;484:45-65. doi: 10.1007/978-1-59745-398-1_4.

PMID:
18592172
42.

Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor.

Voelter V, Rufer N, Reynard S, Greub G, Brookes R, Guillaume P, Grosjean F, Fagerberg T, Michelin O, Rowland-Jones S, Pinilla C, Leyvraz S, Romero P, Appay V.

Int Immunol. 2008 Aug;20(8):1087-96. doi: 10.1093/intimm/dxn066. Epub 2008 Jun 23.

PMID:
18573812
43.

An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain.

Voelter V, Pica A, Laurent J, Rimoldi D, Bouzourene H, Sajadi A, Matter M, Romero P, Rufer N, Speiser DE.

Cancer Immun. 2008 Mar 27;8:6. No abstract available.

44.

Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen.

Speiser DE, Baumgaertner P, Voelter V, Devevre E, Barbey C, Rufer N, Romero P.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3849-54. doi: 10.1073/pnas.0800080105. Epub 2008 Mar 4. Erratum in: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10632.

45.

The proteolytic activity of the paracaspase MALT1 is key in T cell activation.

Rebeaud F, Hailfinger S, Posevitz-Fejfar A, Tapernoux M, Moser R, Rueda D, Gaide O, Guzzardi M, Iancu EM, Rufer N, Fasel N, Thome M.

Nat Immunol. 2008 Mar;9(3):272-81. doi: 10.1038/ni1568. Epub 2008 Feb 10.

PMID:
18264101
46.

Assessing ageing of individual T lymphocytes: mission impossible?

Iancu EM, Speiser DE, Rufer N.

Mech Ageing Dev. 2008 Jan-Feb;129(1-2):67-78. Epub 2007 Oct 30. Review.

PMID:
18048082
47.

Sensitive gene expression profiling of human T cell subsets reveals parallel post-thymic differentiation for CD4+ and CD8+ lineages.

Appay V, Bosio A, Lokan S, Wiencek Y, Biervert C, Küsters D, Devevre E, Speiser D, Romero P, Rufer N, Leyvraz S.

J Immunol. 2007 Dec 1;179(11):7406-14.

48.

In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration.

Derré L, Bruyninx M, Baumgaertner P, Devevre E, Corthesy P, Touvrey C, Mahnke YD, Pircher H, Voelter V, Romero P, Speiser DE, Rufer N.

J Immunol. 2007 Aug 15;179(4):2368-79.

49.

Selecting highly affine and well-expressed TCRs for gene therapy of melanoma.

Jorritsma A, Gomez-Eerland R, Dokter M, van de Kasteele W, Zoet YM, Doxiadis II, Rufer N, Romero P, Morgan RA, Schumacher TN, Haanen JB.

Blood. 2007 Nov 15;110(10):3564-72. Epub 2007 Jul 27.

50.

Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.

Appay V, Voelter V, Rufer N, Reynard S, Jandus C, Gasparini D, Lienard D, Speiser DE, Schneider P, Cerottini JC, Romero P, Leyvraz S.

J Immunother. 2007 Feb-Mar;30(2):240-50.

PMID:
17471171

Supplemental Content

Support Center